181,532 results on '"Neoplasm recurrence, local"'
Search Results
2. Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
- Published
- 2024
3. Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. (NEORISK)
- Published
- 2024
4. Recurrences After Standard EMR vs Plus Thermal Ablation EMR (RESPECT)
- Author
-
Maas Hospital Pantein, Evangelisches Krankenhaus Düsseldorf, Catharina Ziekenhuis Eindhoven, Bernhoven Hospital, Maasstad Hospital, St Jansdal Hospital, and Bravis Hospital
- Published
- 2023
5. SLNB After Neoadjuvant Treatment in Node Positive Patients
- Author
-
Ana Car Peterko, general surgeon
- Published
- 2023
6. Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort
- Author
-
Goran Bencina, Rolf Billeskov, Rasmine Bak, Ahmed Al‐Sabbagh, Julie Højgaard Pedersen, Marina Lunetcas, Emma Heeno, Sara Tolouee, Tuba Ashraf, Niels Fristrup, and Nessn Azawi
- Subjects
carcinoma, renal cell ,KEYNOTE‐564 trial ,neoplasm metastasis ,neoplasm recurrence, local ,nephrectomy ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Objectives This study aimed to characterize the demographic and clinical features of patients with renal cell carcinoma (RCC) post‐surgery for localized or locally advanced disease in a national Danish cohort, with a specific focus on describing recurrence patterns in a subgroup aligned with the adjuvant KEYNOTE‐564 trial classification. Methods This was a retrospective analysis of the Danish Renal Cancer (DaRenCa) database. Eligible subjects were individuals with an RCC diagnosis between January 2014 and December 2017 who subsequently underwent radical or partial nephrectomy. Variables of interest were demographic and clinical characteristics, rates and sites of recurrence. Recurrence rates were also assessed in a subpopulation stratified using the risk classifications of the KEYNOTE‐564 trial. Results A total of 2164 RCC patients were identified. Most patients (84.8%) had non‐metastatic RCC (stage M0). A recurrence was observed in 250 of the M0 patients (13.6%). Patients with a recurrence were older, male, had a higher tumour stage, had undergone radical nephrectomy and had a higher Leibovich score. The majority (74.8%) of M0 patients had recurrence at distant metastatic sites. A total of 392 patients were stratified by the KEYNOTE‐564 risk classification: 335 intermediate‐high risk, 17 high risk and 40 M1 NED (metastatic with no evidence of disease). Recurrence was observed in 37.0%, 88.2% and 27.5% of these risk groups, respectively. Conclusions This study elucidates the rates and determinants of post‐surgical RCC recurrence in Denmark, underscoring the potential of adjuvant immunotherapy in refining therapeutic strategies, identifying suitable beneficiaries and minimizing overtreatment risks in RCC care.
- Published
- 2024
- Full Text
- View/download PDF
7. Incidence, Risk Factor, Treatment and Overall Survival of Locally Recurrent Rectal Cancer
- Author
-
Hidde Swartjes, Researcher in training
- Published
- 2023
8. Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up (TAM-01)
- Author
-
Associazione Italiana per la Ricerca sul Cancro, European Institute of Oncology, and Andrea DeCensi, Medical Oncology Director
- Published
- 2023
9. Imaging of pancreatic ductal adenocarcinoma – An update for all stages of patient management
- Author
-
Carlos Bilreiro, Luísa Andrade, Inês Santiago, Rui Mateus Marques, and Celso Matos
- Subjects
Pancreatic carcinoma ,Neoplasm staging ,Neoadjuvant therapy ,Patient care team ,Neoplasm recurrence, Local ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a common and lethal cancer. From diagnosis to disease staging, response to neoadjuvant therapy assessment and patient surveillance after resection, imaging plays a central role, guiding the multidisciplinary team in decision-planning. Review aims and findings: This review discusses the most up-to-date imaging recommendations, typical and atypical findings, and issues related to each step of patient management. Example cases for each relevant condition are presented, and a structured report for disease staging is suggested. Conclusion: Despite current issues in PDAC imaging at different stages of patient management, the radiologist is essential in the multidisciplinary team, as the conveyor of relevant imaging findings crucial for patient care.
- Published
- 2024
- Full Text
- View/download PDF
10. Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT) (HIOB)
- Author
-
LKH Klagenfurt, Poznan University of Medical Sciences, San Filippo Neri General Hospital, Avera McKennan Hospital & University Health Center, St. Luke's Hospital ,Cedar Rapids, US, A.O.U. San Giovanni Battista di Torino, Italy, IRCCS Cancer Referral Center of Basilicata, Heinrich-Heine University, Duesseldorf, St. Elisabeth-Hospital Köln-Hohenlind, Germany, S.C. Radiotherapia Aziendale Umbria, Italy, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Fondazione Salvatore Maugeri, Marien Hospital Düsseldorf, Azienda Ospedaliero Universitaria Maggiore della Carita, Philipps University Marburg Medical Center, Istituti Tumori Giovanni Paolo II, University Hospital of Ferrara, and Gerd Fastner, Assoc. Prof., MD
- Published
- 2022
11. 肝细胞癌复发进程中DNA修复调节的蛋白质组学分析及验证.
- Author
-
常 凯, 王艳艳, 江忠勇, 孙 巍, 刘晨霞, 那琬琳, 许宏宣, 谢 静, 刘 媛, and 陈 敏
- Abstract
To investigate the role and mechanism of DNA repair regulation in the process of hepatocellular carcinoma (HCC) recurrence. Methods HCC tissue samples were collected from the patients with recurrence within two years or the patients with a good prognosis after 5 years, and the Tandem Mass Tag-labeled quantification proteomic study was used to analyze the differentially expressed proteins enriched in the four pathways of DNA replication, mismatch repair, base excision repair, and nucleotide excision repair, and the regulatory pathways and targets that play a key role in the process of HCC recurrence were analyzed to predict the possible regulatory mechanisms. The independent samples t-test was used for comparison of continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results For the eukaryotic replication complex pathway, there were significant reductions in the protein expression levels of MCM2(P=0.018), MCM3(P=0.047), MCM4(P=0.014), MCM5(P=0.008), MCM6(P=0.006), MCM7(P=0.007), PCNA (P=0.019), RFC4(P=0.002), RFC5(P<0.001), and LIG1 (P=0.042) ; for the nucleotide excision repair pathway, there were significant reductions in the protein expression levels of PCNA (P=0.019), RFC4(P=0.002), RFC5(P<0.001), and LIG1(P=0.042) ; for the base excision repair pathway, there were significant reductions in the protein expression levels of PCNA (P=0.019) and LIG1(P=0.042) in the HCC recurrence group; for the mismatch repair pathway, there were significant reductions in the protein expression levels of MSH2(P=0.026), MSH6(P= 0.006), RFC4 (P=0.002), RFC5 (P<0.001), PCNA (P=0.019), and LIG1 (P=0.042) in recurrent HCC tissue. The differentially expressed proteins were involved in the important components of MCM complex, DNA polymerase complex, ligase LIG1, long patch base shear repair complex (long patch BER), and DNA mismatch repair protein complex. The clinical sample validation analysis of important differentially expressed proteins regulated by DNA repair showed that except for MCM6 with a trend of reduction, the recurrence group also had significant reductions in the relative protein expression levels of MCM5(P=0.008), MCM7(P=0.007), RCF4(P=0.002), RCF5(P<0.001), and MSH6(P=0.006) . Conclusion There are significant reductions or deletions of multiple complex protein components in the process of DNA repair during HCC recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma.
- Author
-
Long, Haiyi, Zhou, Xiaoyu, Zhang, Xiaoer, Ye, Jieyi, Huang, Tongyi, Cong, Longfei, Xie, Xiaoyan, and Huang, Guangliang
- Subjects
- *
CONTRAST-enhanced ultrasound , *IMAGE fusion , *THREE-dimensional imaging , *CATHETER ablation , *CANCER invasiveness - Abstract
Purpose: To compare the efficiency of three-dimensional (3D) and two-dimensional (2D) contrast-enhanced ultrasound (CEUS)–derived techniques in evaluating the ablative margin (AM) after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: In total, 98 patients with 98 HCCs were enrolled. The 2D CEUS point-to-point imaging (2D CEUS-PI) was conducted by comparing the pre- and post-RFA 2D CEUS images manually, and the 3D CEUS fusion imaging (3D CEUS-FI) was conducted by fusing the pre- and post-RFA 3D CEUS images automatically. These two techniques were compared in distinguishing an adequate AM ≥ 5 mm. Risk factors for local tumor progression (LTP) after RFA were analyzed by the Kaplan–Meier method with log-rank test. Results: The mean registration time of 3D CEUS-FI and 2D CEUS-PI was 5.0 and 9.3 min, respectively (p < 0.0001). The kappa coefficient was 0.680 for agreement between 2D CEUS-PI and 3D CEUS-FI in the evaluation of AM (p < 0.0001). Tumors with AM < 5 mm by 2D CEUS-PI were all identified as AM < 5 mm by 3D CEUS-FI. Nonetheless, 16 (26%) tumors identified as AM ≥ 5 mm by 2D CEUS-PI were re-classified as AM < 5 mm by 3D CEUS-FI. During a median follow-up time of 31.2 months (range, 3.2–66.0 months), LTP was identified in 8 tumors. The estimated 1-/2-/3-year cumulative incidence of LTP was 4.4%, 8.1%, and 10.3%, respectively. Higher estimated cumulative incidence of LTP was identified in tumors with AM < 5 mm by 2D CEUS-PI (at 3-year, 27.2% vs 0%; p < 0.001), and by 3D CEUS-FI (at 3-year, 20.7% vs 0%; p = 0.004). Conclusion: 3D CEUS-FI excelled in the evaluation of AM when compared with 2D CEUS-PI. With equivalent efficacy in the prediction of LTP, 3D CEUS-FI was superior to 2D CEUS-PI for its automatic and time-saving procedure. Clinical relevance statement: 3D CEUS fusion imaging may serve as an effective tool in evaluating ablative margin and predicting local tumor progression after RFA in HCC. Key Points: • Both 2D and 3D CEUS–derived techniques could evaluate ablative margin (AM) after RFA for hepatocellular carcinoma. • 3D CEUS fusion imaging was more precise in the evaluation of AM compared to 2D CEUS point-to-point imaging, with advantages of its automatic and time-saving procedure. • An inadequate AM < 5 mm evaluated by CEUS-derived techniques was the only risk factor of LTP after RFA for hepatocellular carcinoma (p < 0.001 for 2D CEUS point-to-point imaging, and p = 0.004 for 3D CEUS fusion imaging). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. 胰腺导管腺癌行腹腔镜下胰十二指肠切除术后早期复发的 列线图模型及其预测价值分析.
- Author
-
刘舜, 谢诚, and 刘亚辉
- Abstract
Objective To investigate the risk factors for early tumor recurrence after laparoscopic pancreaticoduodenectomy (LPD) in patients with pancreatic ductal adenocarcinoma (PDAC), and to establish a predictive model. Methods A retrospective analysis was performed for the clinical data of 240 PDAC patients who underwent LPD in The First Hospital of Jilin University from April 2016 to July 2022, with early postoperative tumor recurrence (time to recurrence ≤12 months) as the study outcome. The patients were randomly divided into training group with 168 patients and validation group with 72 patients at a ratio of 7∶3. In the training group, there were 70 patients (41.67%) with early postoperative recurrence and 98 (58.33%) without early recurrence, and in the validation group, there were 32 (44.44%) with early postoperative recurrence and 40 (55.56%) without early recurrence. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups; a logistic regression analysis was used to investigate the risk factors for early postoperative recurrence; the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to evaluate the discriminatory ability of the model, with AUC>0.75 indicating that the model had adequate discriminatory ability. The Bootstrap resampling method was used for validation after 1 000 times of random sampling, and the model was validated again in the validation group. The calibration curve and the Hosmer-Lemeshow goodness-of-fit test were used to evaluate the degree of calibration, and the decision curve analysis was used to evaluate clinical practicability. Results The univariate and multivariate analyses showed that preoperative CA19-9 level≥37 U/mL (odds ratio [OR]=6.265, 95% confidence interval [CI]: 1.938 — 20.249, P<0.05), maximum tumor diameter >3 cm( OR=10.878, 95%CI: 4.090 — 28.932, P<0.05), poor tumor differentiation( OR=3.679, 95%CI: 1.435 — 9.433, P< 0.05), lymph node metastasis( OR=0.209, 95%CI: 0.080 — 0.551, P<0.05), and absence of adjuvant chemotherapy after surgery( OR= 0.167, 95%CI: 0.058 — 0.480, P<0.05). A nomogram model was constructed based on these factors; the ROC curve analysis showed that the model had an AUC of 0.895 (95%CI: 0.846 — 0.943, P<0.001), and the calibration curve and the Hosmer-Lemeshow test showed that the model had a good degree of calibration (P=0.173). The decision curve analysis showed that the nomogram had a good clinical application value. Conclusion Preoperative CA19-9 level ≥37 U/mL, maximum tumor diameter >3 cm, poor tumor differentiation, lymph node metastasis, and absence of adjuvant chemotherapy after surgery are independent risk factors for the early recurrence of PDAC after LPD, and the nomogram model established based on these factors can effectively predict early postoperative recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. The feasibility of endoscopic resection for colorectal laterally spreading tumors.
- Author
-
Chen, Xingcen, Peng, Dongzi, Liu, Deliang, and Li, Rong
- Abstract
The present study aimed to investigate the feasibility and safety of endoscopic resection for colorectal laterally spreading tumors (LSTs) in different size groups. This retrospective study included 2699 patients with LSTs who underwent endoscopic treatment at the Second Xiangya Hospital of Central South University from May 2012 to February 2022. The patient baseline and procedure outcomes were compared between the < 5 cm group, 5–10 cm group, and ≥ 10 cm group. Meanwhile, lesions larger than 5 cm in diameter were longitudinally compared for endoscopic safety using ESD with surgical operation outcomes. There were 2105 patients in the < 5 cm group, 547 patients in the 5–10 cm group, and 47 patients in the ≥ 10 cm group. En bloc resection and R0 resection rates, the incidence of adverse events, length of stay (LOS), and medical costs significantly differed between the groups (P < 0.01). Comorbidity of diabetes or hypertension, history of antithrombotic drug use, lesion size, location, gross type, endoscopic procedures selection, and circumferential extent of the mucosal defect were independent risk factors for delayed bleeding (P < 0.05). En bloc resection, R0 resection, and lesion canceration were associated with local recurrence. For lesions larger than 5 cm in diameter, ESD had similar R0 resection and local recurrence rates compared with a surgical operation but a lower en bloc rate, LOS, and medical costs. Expert endoscopists can significantly increase en bloc and R0 resection rates and reduce the incidence of adverse events. Endoscopic resection results distinguish in different size groups of colorectal LSTs, yet its safety and feasibility are not inferior to a surgical operation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
- Published
- 2022
16. Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars
- Author
-
Mafalda Cainé João, Medical Doctor
- Published
- 2022
17. Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer
- Author
-
Hidde Swartjes, Researcher in training
- Published
- 2022
18. Relation between Delay Time to Surgical Treatment of Prostate Cancer and Disease Recurrence Risk
- Author
-
Denny Fabrício Magalhães Veloso, Denise Sena Veloso, and André Felipe Zuccolo Barragat de Andrade
- Subjects
Prostatic Neoplasms ,Prostatectomy ,Time-to-Treatment ,Disease Progression ,Neoplasm Recurrence, Local ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction: There is no consensus in the literature on a reasonable delay time from diagnosis to radical prostatectomy (RP) surgery, without worsening the prognosis. Objective: To evaluate the influence of the delay on the risk of disease recurrence in patients with acinar adenocarcinoma of the prostate treated with RP. Method: Four hundred and twelve patients undergoing RP were retrospectively evaluated. Of these, 172 were excluded due to incomplete data and another 28 due to preoperative staging as high-risk prostate cancer (PSA > 10 ng/mL or Gleason score on biopsy > 7). Pre-and postoperative stagings were compared and survival analysis was performed using the Kaplan-Meier method to investigate the influence of time on discordance between pre- and postoperative stagings. Results: For the 212 patients of the sample, the average time from diagnosis to RP was 176.1 ± 120.2 days (median 145.5 days), ranging from 29 to a maximum of 798 days. The Kaplan-Meier curve indicated that the cancer worsened the longer the delay between diagnosis and surgery. Patients undergoing surgery within 60 days had an approximately 95% probability of not increasing the initial risk of recurrence. This number fell to 80%, 70% and 50% in patients operated on up to 100, 120 and 180 days, respectively. Conclusion: Delay in performing RP represents a continuous risk of relapse. The ideal time for RP is up to 60 days from prostate biopsy, as the probability of upstaging is less than 5% in this period.
- Published
- 2024
- Full Text
- View/download PDF
19. Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer (TARGIT-E)
- Author
-
Elena Sperk, MD, PD Dr. med.
- Published
- 2022
20. A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study—UroCCR 80).
- Author
-
Cazalas, Grégoire, Klein, Clément, Piana, Gilles, De Kerviler, Eric, Gangi, Afshin, Puech, Philippe, Nedelcu, Cosmina, Grange, Remi, Buy, Xavier, Jegonday, Marc-Antoine, Bigot, Pierre, Bensalah, Charles Karim, Gaillard, Victor, Pignot, Géraldine, Paparel, Philippe, Badet, Lionel, Michiels, Clément, Bernhard, Jean Christophe, Rouviere, Olivier, and Grenier, Nicolas
- Subjects
- *
NEPHRECTOMY , *RENAL cell carcinoma , *RENAL cancer , *CATHETER ablation - Abstract
Objective: Renal cell carcinomas represent the sixth- and tenth-most frequently diagnosed cancer in men and women. Recently, percutaneous-guided thermal ablations have proved to be as effective as partial nephrectomy and safer for treating small renal masses (i.e., < 3 cm). This study compared the perioperative and recurrence outcomes of percutaneous thermal ablation (TA) and robotic-assisted partial nephrectomy (RAPN) for the treatment of T1b renal cell carcinomas (4.1–7 cm). Methods: Retrospective data from 11 centers on the national database, between 2010 and 2020, included 81 patients treated with thermal ablation (TA) and 308 patients treated with RAPN for T1b renal cell carcinoma, collected retrospectively and matched for tumor size, histology results, and the RENAL score. TA included cryoablation and microwave ablation. Endpoints compared the rate between the two groups: local recurrence, metastases, complications, renal function decrease, and length of hospitalization. Results: After matching, 75 patients were included in each group; mean age was 76.6 (± 9) in the TA group and 61.1 (± 12) in the RAPN group, including 69.3% and 76% men respectively. The local recurrence (LR) rate was significantly higher in the TA group than in the PN group (14.6% vs 4%; p = 0.02). The LR rate was 20% (1/5) after microwave ablation, 11.1% (1/9) after radiofrequency ablation, and 14.7% (9/61) after cryoablation. The major complication rate (Clavien–Dindo ≥ 3) was higher following PN than after TA (5.3% vs 0%; p < 0.001). Metastases, eGFR decrease, and length of hospitalization did not differ significantly between the two groups. Conclusions: The local recurrence rate was significantly higher after thermal ablation; however, thermal ablation resulted in significantly lower rates of complications. Summary statement: Thermal ablation and robotic-assisted partial nephrectomy are effective treatments for T1b renal cancer; however, the local recurrence rate was higher after thermal ablation. Key Points: • The local recurrence rate was significantly higher in the thermal ablation group than in the partial nephrectomy group. • The major complication rate (Clavien–Dindo ≥ 3) was higher following PN than after TA (5.3% vs. 0%; p < 0.001). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
- Author
-
Shu lian Wang, Professor
- Published
- 2022
22. 复发性直肠阴道隔畸胎瘤一例并文献复习.
- Author
-
梁燕凯, 刘君, 于淼, 冀祯, and 路夷平
- Abstract
Teratoma is a common germ cell tumor that develops from germ cells with multiple differentiation potentials. It can be seen in multiple tissues and organs, and the gonad teratoma is the most common. It is rare to develop outside the gonad, especially in the rectovaginal septum. There are few reports of postoperative recurrence of gonad teratoma in literatures. We reported a case of recurrent mature teratoma of rectovaginal septum treated in the surgery department of our hospital. The clinical data were retrospectively analyzed, including clinical symptoms, signs and related auxiliary examinations. In addition, the domestic and foreign literatures on rectovaginal septum teratoma were summarized from the aspects of clinical characteristics, diagnosis, treatment and prognosis. The case report and literature review provide us a practical reference for the future clinical studies on extradadal teratoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Refractory paraneoplastic hypercalcaemia responding to cinacalcet
- Author
-
Preet Mukesh Shah, Irum Rasool, and Deirdre Maguire
- Subjects
Urinary Bladder Neoplasms ,Parathyroid Hormone ,Hypercalcemia ,Humans ,Female ,Bone Neoplasms ,General Medicine ,Cinacalcet ,Neoplasm Recurrence, Local - Abstract
A woman in her late 70s presented with an increased frequency of micturition, suprapubic pain and weight loss. She was found to be having advanced cancer of the urinary bladder, coupled with bilateral hydronephrosis.Whilst undergoing surgical intervention for the latter, she was incidentally found to be having hypercalcaemia. This was found to be paraneoplastic in nature, possibly due to elevated parathyroid hormone related peptide with no evidence of bone metastasis. The histology of the resected tumour revealed squamous and sarcomatoid differentiation. Her hypercalcaemia initially responded to intravenous fluids, and later on zolendronate,but the problem recurred again, with the response to a repeat dose of zolendronate and even denosumab being unsatisfactory. As a last resort cinacalcet was started, and although there was a good response to it, our patient sadly died a few weeks later.We believe our case to be the first case of hypercalcaemia associated with isolated bladder cancer which showed a successful response to cinacalcet.
- Published
- 2024
24. Partial Breast Versus no Irradiation for Women With Early Breast Cancer
- Author
-
Danish Cancer Society, Danish Center for Interventional Research in Radiation Oncology (CIRRO), and Birgitte Offersen, Professor, PhD, MD
- Published
- 2020
25. Epidural Anesthesia-analgesia and Long-term Survival After Lung Cancer Surgery
- Author
-
Dong-Xin Wang, Professor
- Published
- 2020
26. Randomized Trial of Accelerated Partial Breast Irradiation
- Author
-
Shu lian Wang, Professor
- Published
- 2020
27. 125I Radioactive Seed Localization vs. Conventional Surgery for the Treatment of Mesenchymal Tumours: A Propensity Score Matching Analysis.
- Author
-
Barranquero, Alberto G, Corral Moreno, Sara, Martínez Lorca, Alberto, Hernández-Cosido, Lourdes, Rioja Martín, María Eugenia, Mena Mateos, Antonio, Cabañas Montero, Jacobo, and Fernández-Cebrián, Jose María
- Abstract
Purpose: Radioguided localization can assist the surgery of hard-to-find lesions. The aim was to evaluate the results of the 125I Radioactive Seed Localization (RSL) technique to guide a margin-free tumoral resection of mesenchymal tumours compared to conventional surgery and its influence in oncological outcomes. Methods: Retrospective observational study of all consecutive patients who underwent 125I RSL for the surgery of a mesenchymal tumour from January 2012 to January 2020 in a tertiary referral centre in Spain. The control group was formed by patients with conventional surgery in the same period and centre. A Propensity Score matching at 1:4 ratio selected the cases for analysis. Results: A total of 10 lesions excised in 8 radioguided surgeries were compared to 40 lesions excised in 40 conventional surgeries, with equal proportion of histological subtypes in each group. There was a higher proportion of recurrent tumours in the RSL group (80 % [8/10] vs. 27.5 % [11/40]; p: 0.004). An R0 was achieved in 80 % (8/10) of the RSL group and 65 % (26/40) of the conventional surgery group. The R1 rate was 0 % and 15 % (6/40), and the R2 rate was 20 % (2/10 and 8/40) in the RSL group and conventional surgery group, respectively (p: 0.569). No differences were detected in disease-free or overall survival between the different histological subtypes in the subgroup analysis. Conclusion: The 125I RSL technique of a challenging sample of mesenchymal tumours achieved a similar margin-free tumoral resection and oncological outcomes as conventional surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Need for adjuvant radiotherapy in oral cancer: depth of invasion rather than tumor diameter.
- Author
-
Riemenschnitter, Cosima E., Morand, Grégoire B., Schouten, Charlotte S., Rupp, Niels J., Balermpas, Panagiotis, Gander, Thomas, and Broglie Däppen, Martina A.
- Subjects
- *
ORAL cancer , *TUMOR classification , *CANCER radiotherapy , *SQUAMOUS cell carcinoma , *OVERALL survival - Abstract
Purpose: The 8th edition of the TNM Cancer Staging Manual incorporates depth of invasion (DOI) into the pathologic tumor classification for oral squamous cell carcinoma (OSSC). While deep invading tumors with small tumor diameters (TD) have been categorized as early stage tumors in the 7th edition, they are now upstaged, potentially influencing the decision to initiate adjuvant radiotherapy (RT). Methods: OSCC patients surgically treated with curative intent between 2010 and 2019 were consecutively included. Tumors were staged based on TD only (according to the 7th edition TNM Cancer Staging Manual), then restaged based solely on DOI. Results: Of the 133 included patients, 58 patients (43.6%) had a different pT-stage when using DOI instead of TD for staging (upstaging in 23.3%). Overall survival (OS) was significantly worse in patients who were upstaged with DOI. In addition, stratification by adjuvant RT showed significant worse OS in upstaged patients without receiving adjuvant RT. Conclusions: DOI seems to be an import indicator for adjuvant RT in OSCC-patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Can "no-touch" radiofrequency ablation for hepatocellular carcinoma improve local tumor control? Systematic review and meta-analysis.
- Author
-
Kim, Tae-Hyung, Lee, Jeong Min, Lee, Dong Ho, Joo, Ijin, Park, Sae-Jin, and Yoon, Jung Hee
- Subjects
- *
CATHETER ablation , *CANCER invasiveness , *HEPATOCELLULAR carcinoma , *CANCER diagnosis , *CANCER treatment - Abstract
Objectives: Percutaneous radiofrequency ablation (RFA) is one of the curative treatments for hepatocellular carcinoma (HCC), but local tumor progression (LTP) has been a main limitation of RFA. This study aims to evaluate the LTP of percutaneous no-touch RFA (NtRFA) for HCC ≤ 5 cm and compare with conventional RFA (intratumoral puncture) through a systematic review and meta-analysis. Methods: MEDLINE, EMBASE, and Cochrane Library were searched for studies on percutaneous NtRFA for HCC ≤ 5 cm. The pooled proportions of the overall and cumulative incidence rates at 1, 2, and 3 years for LTP after NtRFA were assessed using a random-effects model. For studies comparing NtRFA with conventional RFA, relative risks (RR) and hazard ratios (HR) were meta-analytically pooled with LTP as the outcome. Results: Twelve studies with 900 patients were included. The pooled overall rate of LTP after NtRFA was 6% (95% CI, 4–8%). The pooled 1-, 2-, and 3-year cumulative incidence rates of LTP were 3% (95% CI, 2–5%), 5% (95% CI, 3– 9%), and 8% (95% CI, 6–11%), respectively. Compared to conventional RFA, the pooled RR and HR of LTP were 0.26 (95% CI, 0.16–0.41) and 0.28 (95% CI, 0.11–0.70), respectively (both p < 0.01). Subgroup analysis including only randomized controlled studies also showed better local tumor control of NtRFA with HR of 0.13 (95% CI, 0.14–0.42). Conclusions: Percutaneous NtRFA is an effective treatment for HCC ≤ 5 cm with an overall LTP rate of 6% and provides lower LTP compared with conventional RFA. Key Points: • The pooled 1-, 2-, and 3-year cumulative incidence rates of local tumor progression after no-touch radiofrequency ablation for HCC ≤ 5 cm were 3% (95% CI, 2–5%), 5% (95% CI, 3–9%), and 8% (95% CI, 6–11%). • No-touch radiofrequency ablation had significantly lower rates of local tumor progression compared to conventional radiofrequency ablation (hazard ratio, 0.28; 95% CI, 0.11–0.70; relative risk, 0.26; 95% CI, 0.16–0.41; p < 0.01, respectively). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Prolapsing vaginal fibroepithelial polyp
- Author
-
Angela Leffelman and Sandra Valaitis
- Subjects
Vaginal Neoplasms ,Polyps ,Humans ,Female ,General Medicine ,Neoplasms, Squamous Cell ,Neoplasm Recurrence, Local ,Pelvic Organ Prolapse - Abstract
Although uncommon, vaginal fibroepithelial polyps can present as prolapsing vaginal tissue, causing discomfort and anxiety. Surgical excision of the polyps can provide a minimally invasive solution. In this case, we describe a nulliparous female in late adolescence who presented for evaluation of tissue protruding through the vagina. On exam, a 5×4 cm fibroepithelial polyp was extending from the distal posterior vagina on a broad stalk. Successful transperineal surgical excision was performed. Fibroepithelial polyps, although uncommon, can be a cause for prolapsing vaginal tissue and should be part of the differential diagnosis, especially in patients who have no risk factors for pelvic organ prolapse. They can be excised vaginally, alleviating symptoms and distress. Because they sometimes recur, continued surveillance with gynaecological exams is recommended.
- Published
- 2024
31. 可切除胰腺癌术前评分分级体系的建立与应用.
- Author
-
王成方, 王之江, and 王伟林
- Abstract
Objective To investigate the risk factors for early recurrence of resectable pancreatic cancer and the establishment and application of a grading system. Methods A retrospective case-control study was conducted among 303 patients with resectable pancreatic cancer who underwent radical resection in Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, from March 2015 to June 2021, and according to the presence or absence of early recurrence (within 6 months after surgery), the 283 patients directly operated on were divided into early recurrence group with 95 patients and non-early recurrence group with 188 patients; 20 patients who received neoadjuvant therapy before surgery were enrolled as neoadjuvant therapy group. Observation indicators included general information, preoperative imaging data, preoperative laboratory data, routine blood test/blood biochemistry and derived indicators, tumor markers, and coagulation markers, and follow-up was conducted to observe recurrence-free survival. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A multivariate Logistic regression analysis was used to investigate the risk factors for early recurrence in patients with pancreatic cancer, and the receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value of each indicator. The Kaplan-Meier curve was plotted, and the Log-rank test was used for comparison of recurrence-free survival time between groups. Results The univariate analysis showed that compared with the non-early recurrence group, the early recurrence group had significantly lower body mass index (BMI) and triglyceride and significantly higher CA19-9, CA242, CA125, and plasma fibrinogen (all P < 0.05). The multivariate logistic regression analysis showed that BMI (odds ratio [OR]=1.150, 95% confidence interval [CI]: 1.038-1.273, P=0.007), plasma fibrinogen (OR=2.513, 95%CI: 1.355-4.663, P=0.003), and CA242 (OR=2.482, 95%CI: 1.067-5.774, P=0.035) were independent risk factors for early recurrence in patients with resectable pancreatic cancer. BMI, CA242, and plasma fibrinogen were included in the grading system, with a cut-off value of 23.00 kg/m², 30.0 U/mL, and 4.00 g/L, respectively. BMI < 23.00 kg/m² was counted as 1 point, otherwise it was counted as 0 point; CA242≥30.00 U/mL was counted as 1 point, otherwise it was counted as 0 point; plasma fibrinogen ≥4.00 g/L was counted as 1 point, otherwise it was counted as 0 point; the total score was 0-3 points. The patients in both the early recurrence group and the non-early recurrence group were scored, and the results showed that the early recurrence group had a significantly higher score than the non-early recurrence group [2(0-3) points vs 1(0-3) point, Z=-5.339, P < 0.001]. The Kaplan-Meier curve analysis showed that there was a significant difference in time to recurrence between groups (χ²=28.116, P < 0.001), and the higher the score, the shorter the expected time to recurrence. The patients with 3 points were defined as high-risk group and those with 0-2 points were defined as low-risk group, and the early recurrence rate was 84.6% in the high-risk group and 31.2% in the low-risk group. Conclusion The grading system based on BMI, plasma fibrinogen, and CA242 can reliably predict postoperative recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Cystic lesion in parotid region: an unexpected diagnosis
- Author
-
Carmelo Saraniti, Gaetano Patti, Vito Rodolico, and Barbara Verro
- Subjects
Parotid Region ,Humans ,Parotid Gland ,Female ,General Medicine ,Neoplasm Recurrence, Local ,Adenolymphoma ,Parotid Neoplasms - Abstract
Benign tumours of salivary glands represent 2%–3% of all tumours and parotid gland is most often affected. Keratocystoma is a rare benign tumour with multilocular cystic lesions filled with keratin materials. Histologically, it is characterised by solid epithelium islands containing keratinised lamellae with multicystic spaces. We report a case of a woman in her mid-70s with painless mass in her left parotid gland which increased in size over 1 year. Ultrasound scan revealed a 38×20 mm diameter hypoanechoic mass. Neck CT with contrast medium and fine needle aspiration were performed with diagnostic hypothesis of Warthin tumour. So, extracapsular parotid dissection with no facial nerve damage was performed. Histological examination revealed a keratocystoma. The patient had a 16-month follow-up without signs of relapse or malignancy. Despite its rarity, keratocystoma must be considered among the possible differential diagnostic hypotheses when we find parotid masses, to ensure the best treatment to the patient.
- Published
- 2024
33. First reported case of corneal infection caused by
- Author
-
Nimish Kumar, Singh, Srikant, Sahu, Smruti Rekha, Priyadarshini, and Himanshu Sekhara, Behera
- Subjects
Actinobacteria ,Male ,Keratitis, Herpetic ,Humans ,Neoplasm Recurrence, Local ,Anti-Bacterial Agents - Abstract
A man in his 20s, with irritation, pain and photophobia in the left eye, was clinically diagnosed with herpes simplex virus nummular keratitis at our institute and advised topical antivirals and corticosteroids, causing resolution of active infiltrates. The infection recurred after 7 months and the patient did not respond to the previous regimen, so corneal scraping was sent for microbiological evaluation. Gram-positive bacilli grew on culture, which were identified as
- Published
- 2024
34. Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma
- Author
-
Binoy Yohannan, Arthi Sridhar, Nghia Nguyen, and Adan Rios
- Subjects
Adult ,Male ,Pyrimidines ,Humans ,Pyrazoles ,Antineoplastic Agents ,General Medicine ,Lymphoma, Mantle-Cell ,Neoplasm Recurrence, Local ,Rituximab ,Protein Kinase Inhibitors - Abstract
Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin's lymphoma with a variable clinical course. Central nervous system (CNS) involvement is a rare and dreaded complication in MCL. We report a case of leptomeningeal relapse of MCL that was successfully treated with a single-agent Bruton’s tyrosine kinase inhibitor. A man in his 50s with MCL was treated with six cycles of bendamustine–rituximab, achieving a complete remission (CR) and was subsequently placed on rituximab maintenance for 2 years. Four years later, he was hospitalised with symptoms of organic brain syndrome. Brain MRI and cerebrospinal fluid analysis confirmed CNS relapse of MCL. He was treated with dexamethasone, ibrutinib 560 mg/day and intrathecal cytarabine with improvement in neurological symptoms, and a follow-up MRI showed CR. The patient was later switched to acalabrutinib due to intolerance to ibrutinib. The patient is tolerating this regimen well, remaining in CR 3 years later.
- Published
- 2024
35. Chemotherapy-induced Sweet's syndrome in a patient with recurrent laryngeal carcinoma
- Author
-
Mahmoud Abdelnabi, Cristina Morataya, Annia Cavazos, and Michelle Tarbox
- Subjects
Neutrophils ,Carcinoma ,Chronic Disease ,Humans ,Antineoplastic Agents ,General Medicine ,Neoplasm Recurrence, Local ,Laryngeal Neoplasms ,Sweet Syndrome - Published
- 2024
36. Fractionated Radiosurgery for Painful Spinal Metastases (DOSIS)
- Author
-
Royal Marsden NHS Foundation Trust
- Published
- 2019
37. Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
- Author
-
Ping Lan, Professor
- Published
- 2019
38. Strabismus Management in Retinoblastoma Survivors
- Author
-
Masoomian, Babak, Shields, Carol L., Esfahani, Hamid Riazi, Khalili, Atefeh, Ghassemi, Fariba, Rishi, Pukhraj, Akbari, Mohammad Reza, Khorrami-Nejad, Masoud, Masoomian, Babak, Shields, Carol L., Esfahani, Hamid Riazi, Khalili, Atefeh, Ghassemi, Fariba, Rishi, Pukhraj, Akbari, Mohammad Reza, and Khorrami-Nejad, Masoud
- Abstract
PURPOSE: To report the result of strabismus surgery in eye-salvaged retinoblastoma (Rb) patients. METHODS: A retrospective case series including 18 patients with Rb and strabismus who underwent strabismus surgery after completing tumor treatment by a single pediatric ophthalmologist. RESULTS: A total of 18 patients (10 females and 8 males) were included with a mean age of 13.3 ± 3.0 (range, 2-39) months at the time tumor presentation and 6.0 ± 1.5 (range, 4-9) years at the time of strabismus surgery. Ten (56%) patients had unilateral and 8(44%) had bilateral involvement and the most common worse eye tumor's group was D (n = 11), C (n = 4), B (n = 2) and E (n = 1). Macula was involved by the tumors in 12 (67%) patients. The tumors were managed by intravenous chemotherapy (n = 8, 47%), intra-arterial chemotherapy (n = 7, 41%) and both (n = 3, 17%). After complete treatment, the average time to strabismus surgery was 29.9 ± 20.5 (range, 12-84) months. Except for one, visual acuity was equal or less than 1.0 logMAR (≤ 20/200) in the affected eye. Seven (39%) patients had exotropia, 11(61%) had esotropia (P = 0.346) and vertical deviation was found in 8 (48%) cases. The angle of deviation was 42.0 ± 10.4 (range, 30-60) prism diopter (PD) for esotropic and 35.7 ± 7.9 (range, 25-50) PD for exotropic patients (P = 0.32) that after surgery significantly decreased to 8.5 ± 5.3 PD in esotropic cases and 5.9 ± 6.7 PD in exotropic cases (P < 0.001). The mean follow-up after surgery was 15.2 ± 2.0 (range, 10-24) months, in which, 3 (17%) patients needed a second surgery. CONCLUSION: Strabismus surgery in treated Rb is safe and results of the surgeries are acceptable and close to the general population. There was not associated with tumor recurrence or metastasis.
- Published
- 2024
39. The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma.
- Author
-
Seddon B, Grange FL, Simões R, Stacey C, Shelly S, Forsyth S, White L, Candish C, Dickinson P, Miah A, Moinuddin SA, Wylie J, and Lopes A
- Subjects
- Humans, Middle Aged, Male, Female, Aged, Adult, Prospective Studies, Fibrosis, Radiation Injuries, Dose Fractionation, Radiation, Organs at Risk radiation effects, Neoplasm Recurrence, Local, Radiotherapy, Intensity-Modulated adverse effects, Sarcoma radiotherapy, Sarcoma surgery, Sarcoma pathology, Sarcoma mortality, Extremities
- Abstract
Purpose: Primary soft tissue sarcoma (STS) is rare, with many tumors occurring in extremities. Local management is limb-sparing surgery and preoperative/postoperative radiation therapy (RT) for patients at high risk of local recurrence. We prospectively investigated late normal tissue toxicity and limb function observed after intensity modulated RT (IMRT) in extremity STS., Methods and Materials: Patients with extremity STS, age ≥16 years. Two treatment cohorts: IMRT 50 Gy in 25 × 2 Gy fractions (preoperative) or 60/66 Gy in 30/33 × 2 Gy fractions (postoperative). The primary endpoint was the rate of grade ≥2 late soft tissue fibrosis (subcutaneous tissue) at 24 months after IMRT (Radiation Therapy Oncology Group late radiation morbidity scoring)., Results: One hundred sixty-eight patients were registered between March 2016 and July 2017. Of those, 159 (95%) received IMRT (106, 67% preoperative RT; and 53, 33% postoperative RT) with a median follow-up of 35.2 months (IQR, 32.9-36.6); 62% men, median age 58 years. Of 111 patients assessable for the primary endpoint at 24 months, 12 (10.8%; 95% CI, 5.7%-18.1%) had grade ≥2 subcutaneous fibrosis. The overall rate at 24 months of Radiation Therapy Oncology Group late skin, bone, and joint toxicity was 7 of 112 (6.3%), 3 of 112 (2.7%), and 10 of 113 (8.8%), respectively, and for Stern's scale edema was 6 of 113 (5.3%). More wound complications were observed with preoperative than postoperative RT (29.2% vs 3.8%). Overall survival at 24 months was 84.6%, and the local recurrence event rate at 24 months was 10%., Conclusions: The rate of grade ≥2 subcutaneous fibrosis at 24 months after IMRT was 10.8%, consistent with other recent trials of IMRT and lower than historically reported rates in patients treated with 3-dimensional conformal RT. This trial provides further evidence for the benefits of IMRT in this patient population., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Pediatric B-cell Non-Hodgkin Lymphoma: The Impact of Therapy Response and Relapse on Outcome. A Single-center Analysis.
- Author
-
Stankiewicz J, Jabłońska A, Treichel P, Demidowicz E, and Styczyński J
- Subjects
- Humans, Child, Male, Female, Adolescent, Child, Preschool, Prognosis, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Retrospective Studies, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Recurrence, Lymphoma, B-Cell therapy, Lymphoma, B-Cell mortality, Lymphoma, B-Cell pathology, Neoplasm Recurrence, Local
- Abstract
Background/aim: Pediatric patients with primary refractory or relapsed B-cell non-Hodgkin lymphoma (B-NHL) have highly unfavorable prognosis. In this study, we retrospectively analyzed outcomes in pediatric B-NHL patients treated in a single center in Poland from 1995 to 2022, with emphasis on therapy results in patients with progression or relapse., Patients and Methods: The primary objectives were a 5-year probability of overall survival (pOS) and a 5-year probability of event-free survival (pEFS). The secondary objectives involved the assessment of prognostic factors., Results: A total of 76 children were eligible for the analysis. The 5-year pOS was 76.7%, and the 5-year pEFS was 72.9%. At diagnosis, elevated lactate dehydrogenase activity, the presence of B symptoms, bone marrow, skeletal or mediastinal involvement, and stage IV disease were associated with inferior outcomes. Nine children experienced progression and four relapse. The 5-year pOS for patients with progression was 38.1%. Two patients treated with hematopoietic stem cell transplantation (HSCT) as part of salvage therapy survived. However, only one out of seven patients who were treated without HSCT survived. The 5-year pOS was 0.0% in patients with relapsed disease., Conclusion: The most significant factor related to outcomes in pediatric B-NHL is therapy response, with a high mortality rate in children with refractory disease and relapse. There is no consensus on the salvage therapy approach; however, HSCT appears to be the optimal choice., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis.
- Author
-
Wu X, Zhang M, Jiang Q, Li M, and Wu Y
- Subjects
- Humans, Anisotropy, Diagnosis, Differential, ROC Curve, Glioma pathology, Glioma diagnostic imaging, Diffusion Tensor Imaging methods, Brain Neoplasms pathology, Brain Neoplasms diagnostic imaging, Neoplasm Recurrence, Local, Disease Progression, Sensitivity and Specificity
- Abstract
Purpose: To evaluate the diagnostic accuracy of diffusion tensor imaging (DTI)-derived metrics mean diffusivity (MD) and fractional anisotropy (FA) in differentiating glioma recurrence from pseudoprogression., Methods: The Cochrane Library, Scopus, PubMed, and the Web of Science were systematically searched. Study selection and data extraction were done by two investigators independently. The quality assessment of diagnostic accuracy studies was applied to evaluate the quality of the included studies. Combined sensitivity (SEN) and specificity (SPE) and the area under the summary receiver operating characteristic curve (SROC) with the 95% confidence interval (CI) were calculated., Results: Seven high-quality studies involving 246 patients were included. Quantitative synthesis of studies showed that the pooled SEN and SPE for MD were 0.81 (95% CI 0.70-0.88) and 0.82 (95% CI 0.70-0.90), respectively, and the value of the area under the SROC curve was 0.88 (95% CI 0.85-0.91). The pooled SEN and SPE for FA were 0.74 (95% CI 0.65-0.82) and 0.79 (95% CI 0.66-0.88), respectively, and the value of the area under the SROC curve was 0.84 (95% CI 0.80-0.87)., Conclusions: This meta-analysis showed that both MD and FA have a high diagnostic accuracy in differentiating glioma recurrence from pseudoprogression., Registration: PROSPERO protocol: CRD42024501146.
- Published
- 2024
- Full Text
- View/download PDF
42. Mitotic spindle positioning protein serves as prognostic biomarker in patients with colorectal cancer.
- Author
-
Li J, Zhang A, Li W, Duan Z, Li S, Fan Y, and Hao H
- Subjects
- Humans, Male, Female, Middle Aged, Prognosis, Aged, Kaplan-Meier Estimate, Lymphatic Metastasis, Immunohistochemistry, RNA, Messenger metabolism, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Colorectal Neoplasms mortality, Biomarkers, Tumor metabolism, Biomarkers, Tumor genetics, Neoplasm Recurrence, Local
- Abstract
Background: Colorectal cancer (CRC) ranks among the most aggressive types of cancer globally. Currently, clinical tumor prognostic biomarkers still lack accuracy. Mitotic spindle positioning (MISP) protein connects microtubules to the actin cytoskeleton and adhesive plaques, playing a critical role in spindle positioning, orientation, and the process of cell division. MISP can regulate the malignant biological functions of pancreatic cancer and intrahepatic cholangiocarcinoma and it acts as biomarker for prognosis, but its role in CRC remains unclear., Methods: This study has collected 37 CRC tissue samples and 37 corresponding adjacent nontumor tissue samples, and 57 additional CRC tissues samples. Clinical data were obtained from the patients with CRC. MISP mRNA and protein expression levels were analyzed in normal control and CRC tissues using the GEPIA and Human Protein Atlas website. MISP protein levels in the collected tissues were analyzed using immunohistochemistry., Results: MISP mRNA and protein expression levels were significantly increased in CRC tissues compared to adjacent nontumor tissues. Higher MISP protein levels were associated with distant metastasis, recurrence, and lower survival rates. Kaplan-Meier analysis showed that high expression levels of MISP protein were associated with recurrence and death in CRC patients. In addition, a high expression level of MISP protein, lymph node metastasis, and distance metastasis were risk factors for recurrence and a poor prognosis in patients with CRC., Conclusion: Elevated MISP protein correlated with tumor metastasis, recurrence, and lower survival rates in patients with CRC, and thus, MISP has the potential to become a prognostic marker for CRC.
- Published
- 2024
- Full Text
- View/download PDF
43. When Seeds Fail: Local Recurrence of Prostate Cancer Within a Seminal Vesicle After Brachytherapy.
- Author
-
Mannar D and Liu W
- Subjects
- Humans, Male, Neoplasm Seeding, Brachytherapy adverse effects, Seminal Vesicles radiation effects, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms pathology, Neoplasm Recurrence, Local
- Published
- 2024
- Full Text
- View/download PDF
44. Retrospective study on endoscopic treatment of recurrent esophageal cancer patients after radiotherapy.
- Author
-
Dou L, Liu Y, Zha B, Zhu J, Zhang Y, He S, and Wang G
- Subjects
- Humans, Male, Middle Aged, Retrospective Studies, Female, Aged, Chemoradiotherapy methods, Adult, Esophageal Neoplasms pathology, Esophageal Neoplasms therapy, Esophageal Neoplasms radiotherapy, Neoplasm Recurrence, Local, Esophagoscopy methods
- Abstract
Background: Esophageal cancer poses a significant health burden globally. Endoscopic treatment has emerged as a viable option for patient ineligible for surgery or experiencing disease recurrence post-radiotherapy., Methods: Patients visiting the Department of Endoscopy at the Cancer Hospital of China Academy of Medical Sciences between March 2009 and March 2024 were retrospectively analyzed. Inclusion criteria encompassed patients with histologically confirmed esophageal cancer who had not undergone surgery, but received radiotherapy or CRT, and subsequently opted for endoscopic treatment. Data on demographics, treatment modalities, recurrence patterns, histopathological characteristics, and outcomes were collected. Statistical analysis was conducted using SPSS 27.0, employing Kolmogorov-Smirnov tests for data normality assessment., Results: Out of 25 included patients, the mean age was 60.29 years, with a predominance of males (88%). Most patients (64%) received chemoradiotherapy (CRT), while the rest underwent radiotherapy alone. The median follow-up duration was 50.92 months, with a median recurrence time of 38.92 months. Majority (56%) presented with a solitary lesion and 76% had negative margins. Histopathological analysis revealed various stages of cancer, with the most common being high-grade squamous epithelial neoplasia (64%). Survival analysis indicated a 72% overall survival rate, with 16% surviving beyond 5-year post-treatment. Approximately, 20% succumbed during the study, primarily due to non-esophageal causes (16%)., Conclusion: Endoscopic treatment shows promise as a therapeutic option for selected esophageal cancer patients, offering favorable outcomes in terms of survival and disease control. Further prospective studies are warranted to validate these findings and optimize patient selection criteria for endoscopic interventions in esophageal cancer management., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
45. Patterns of treatment failure in patients with sinonasal squamous cell carcinoma after chemoradiotherapy.
- Author
-
Wang L, Wang J, Wang T, Li Y, and Song X
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Adult, Aged, 80 and over, Treatment Failure, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell pathology, Neoplasm Recurrence, Local, Chemoradiotherapy methods, Paranasal Sinus Neoplasms therapy, Paranasal Sinus Neoplasms radiotherapy, Paranasal Sinus Neoplasms pathology, Paranasal Sinus Neoplasms mortality
- Abstract
Objectives: To investigate the failure patterns based on precision radiation treatment and to determine the predictive factors of treatment failure for sinonasal squamous cell carcinoma (SNSCC) patients., Methods: This was a retrospective study that included 214 cases of treatment failure from 441 consecutive patients. Two experienced radiation oncologists evaluated the tumour volume of cases with local recurrence. The 5-year overall survival (OS), progression-free survival (PFS) rates, and distant-metastasis-free survival (DMFS) were estimated. Investigations were performed on the factors that predicted local failure or distant metastasis., Results: About 140 (31.7%) patients developed local recurrence, 24 (5.4%) experienced regional failure, and 65 (14.7%) underwent distant metastasis. In-field, marginal, and out-of-field failures occurred in 55.7% (78/140), 33.6% (47/140), and 10.7% (15/140) of patients with local recurrence, respectively. In logistic regression analysis, factors statistically significant for total local failure included treatment mode (P < .01), chemotherapy (P < .01), and surgical margins (P < .01). Primary tumours with poor differentiation (P = .018) and R2 resection margin (P = .009) were more prone to develop distant failure. The 5-year OS, PFS, and DMFS rates were 57.8%, 52.0%, and 56.7% for the whole cohort. In univariate and multivariate analysis, the skull base involvement was an independent predictor for poorer OS and PFS; orbital invasion was an independent predictor for poorer OS., Conclusions: Local recurrence and distant metastasis were the most common failure modes. Treatment mode, chemotherapy, and surgical margins were related to local recurrence. Poor differentiation and R2 resection margin were predictors for distant failure., Advances in Knowledge: Local recurrence is the most common failure pattern in patients with SNSCC who accepted chemoradiotherapy, and marginal and out-of-field failures occurred in 44.3% of patients with local recurrence., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
46. Analysis of re-recurrent rectal cancer after curative treatment of locally recurrent rectal cancer.
- Author
-
Piqeur F, Coolen L, Nordkamp S, Creemers DMJ, Tijssen RHN, Neggers-Habraken AGJ, Rutten HJT, Nederend J, Marijnen CAM, Burger JWA, and Peulen HMU
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Aged, 80 and over, Chemoradiotherapy, Adult, Retrospective Studies, Rectal Neoplasms therapy, Rectal Neoplasms pathology, Rectal Neoplasms radiotherapy, Rectal Neoplasms diagnostic imaging, Neoplasm Recurrence, Local
- Abstract
Purpose: Substantiating data guiding clinical decision making in locally recurrent rectal cancer (LRRC) is lacking, specifically in target volume (TV) definition for chemoradiotherapy (CRT). A case-by-case review of local re-recurrences (re-LRRC) after multimodal treatment for LRRC was performed, to determine location of re-LRRC and assess whether treatment could have been improved., Methods: All patients treated with curative intent for LRRC at the Catharina Hospital Eindhoven from October 2016 onwards, in whom complete imaging of (re-)LRRC and radiotherapy was available, were retrieved. Patients were discussed in plenary meetings with expert colorectal surgeons, radiation oncologists and radiologists. Each case was classified based on re-LRRC location, whether it was in accordance with the (current) radiotherapy protocol, and whether multimodal management would have been different in retrospect., Results: Thirty-three cases were discussed. LRRC treatment was deemed suboptimal in 17/33 patients, due to different target volumes (13/17) and/or different surgery (9/17). 15/33 (46 %) of re-LRRC developed in-field of the prior radiotherapy TV, possibly showing RT-resistant disease. Other re-LRRCs developed out-field (n = 5, 15 %), marginally (n = 6, 18 %), or in a combined fashion (n = 7, 21 %). In retrospect, 48 % of cases were irradiated in line with current TV recommendations. TVs of 13/33 cases would have been altered if irradiated today., Conclusion: This study highlights room for improvement within current standard-ofcare treatment for LRRC. Different surgical management or TVs may have improved outcome in up to half of discussed cases. Further delineation guideline development, incorporating the results from this study, may improve oncological outcome, specifically local control, for LRRC patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer.
- Author
-
Togami S, Furuzono N, Mizuno M, Yanazume S, and Kobayashi H
- Subjects
- Humans, Female, Middle Aged, Adult, Aged, Lymphatic Metastasis, Neoplasm Staging, Robotic Surgical Procedures methods, Indocyanine Green administration & dosage, Neoplasm Recurrence, Local, Laparoscopy methods, Phytic Acid, Young Adult, Treatment Outcome, Organotechnetium Compounds, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms pathology, Sentinel Lymph Node pathology, Sentinel Lymph Node surgery, Sentinel Lymph Node Biopsy methods, Lymph Node Excision methods
- Abstract
Background: Sentinel lymph node navigation surgery, which identifies the sentinel lymph node in early cervical cancers and omits systemic pelvic lymphadenectomy in cases where no lymph node metastasis is present, has recently gained attention. However, there are few reports on lymph node recurrence and the long-term outcomes of cervical cancer surgery performed using sentinel lymph node navigation surgery. In this study, we aimed to evaluate the long-term outcomes of sentinel node navigation surgery for early-stage cervical cancer., Methods: One hundred thirty-eight patients with cervical cancer were enrolled. Sentinel lymph nodes were identified by injecting 99 m Technetium-labeled phytate and indocyanine green into the uterine cervix. Surgery and survival outcomes were also analyzed., Results: The median age and body mass index of the patients were 40 years (20-78) and 21.7 kg/m
2 (16.5-50.4), respectively. Open surgery, laparoscopic surgery, and robotic surgery were performed in 77 (56%), 53 (38%), and 8 (6%) patients, respectively. The overall and bilateral detection rates of the sentinel lymph node were 100% and 94%, respectively. Only one case (0.7%) exhibited lower extremity lymphedema, and pelvic lymphocele was observed in three cases (2.2%). Four cases (3%) experienced recurrence over a median follow-up of 57.5 months (range, 2-115 months), with five-year recurrence-free and overall survival rates of 97% and 97.3%, respectively., Conclusions: Our results demonstrate that sentinel node navigation surgery may be safe and effective for early-stage cervical cancer., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
48. A BRILLIANT-BRCA study: residual breast tissue after mastectomy and reconstruction.
- Author
-
Kaidar-Person O, Faermann R, Polikar D, Cohen K, Bernstein-Molho R, Morrow M, Boersma LJ, Offersen BV, Poortmans P, Sklair-Levy M, and Anaby D
- Subjects
- Humans, Female, Middle Aged, Adult, Neoplasm Recurrence, Local, Aged, Breast surgery, Breast pathology, Breast diagnostic imaging, BRCA2 Protein genetics, Follow-Up Studies, BRCA1 Protein genetics, Retrospective Studies, Breast Neoplasms surgery, Breast Neoplasms pathology, Breast Neoplasms diagnostic imaging, Magnetic Resonance Imaging methods, Mastectomy adverse effects, Mastectomy methods, Mammaplasty methods, Mammaplasty adverse effects
- Abstract
Introduction: Different types of mastectomies leave different amounts of residual breast tissue. The significance of the residual breast volume (RBV) is not clear. Therefore, we developed an MRI tool that allows to easily assess the RBV. In this study we evaluated factors associated with RBV after skin or nipple sparing mastectomy (SSM/NSM) in breast cancer BRCA pathogenic variant (PV) carriers who underwent both therapeutic and risk reducing SSM/NSM and its relation to breast cancer outcomes using an innovative MRI-based tool., Methods: Data of breast cancer BRCA PV who were treated between 2006 and 2020 were retrieved from of the oncogenetics unit databases. Only patients who underwent SSM/NSM and had a postoperative breast MRI available for analysis were included. Data collected included demographics, clinicopathological features, and outcomes. The MRI tool was developed by a breast cancer imaging laboratory. A logistic regression test and 95% confidence interval (CI) were used to assess the associated risk of increased RBV. A forward stepwise linear regression was used to correlate tumour-patient specific factors and RBV, and a Kaplan-Meier curve to show the probability of locoregional relapse., Results: A total of 84 patients undergoing 89 mastectomies were included. At a median follow-up of 98 months, 5 local, 2 regional, and 4 distant recurrences were observed. RBV was not significantly related with breast cancer outcomes (p value = NS). A higher body mass index (BMI) was associated with a higher RBV (p < 0.0001). A larger number of involved axillary nodes was associated with a smaller RBV (p = 0.025). The RBV on the risk-reducing mastectomy side was significantly higher compared to the breast cancer side (p value = 0.007). Local recurrences occurred in the vicinity of the primary tumour., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
49. Prognostic factors in pulmonary metastases resection from colorectal cancer: impact of right-sided colon cancer and early recurrence.
- Author
-
Tsukamoto Y, Nakada T, Shigemori R, Kato D, Shibazaki T, Mori S, Odaka M, and Ohtsuka T
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Risk Factors, Time Factors, Metastasectomy, Prognosis, Colonic Neoplasms surgery, Colonic Neoplasms pathology, Colonic Neoplasms mortality, Treatment Outcome, Aged, 80 and over, Lung Neoplasms surgery, Lung Neoplasms mortality, Lung Neoplasms secondary, Lung Neoplasms pathology, Neoplasm Recurrence, Local, Colorectal Neoplasms pathology, Colorectal Neoplasms surgery, Colorectal Neoplasms mortality, Pneumonectomy mortality
- Abstract
Objective: This retrospective cohort study aimed to explore the surgical outcomes and prognostic factors of resection of pulmonary metastases (PM) from colorectal cancer (CRC)., Methods: Overall, 60 patients who underwent resection of PM from CRC between 2015 and 2021 at two institutions were reviewed. The primary outcome were overall survival (OS) and early recurrence after PM resection. The association between OS and right-sided colon cancer (RCC) was investigated. Early recurrence after PM resection was defined as recurrence within one year., Results: The 5-year OS after CRC resection was 83.8% (95% confidence interval [CI] 67.5-92.4) and after PM resection was 69.4% (95% CI 47.5-83.6). In total, 25 patients had recurrence after PM resection (16 within 1 year and 9 after 1 year). In multivariable analysis for OS, RCC (hazard ratio [HR] 4.370, 95% CI 1.020-18.73; p = 0.047) and early recurrence after resection of PM (HR 17.23, 95% CI 2.685-110.6; p = 0.003) were risk factors for poor OS. In multivariable analysis for early recurrence after PM resection, higher value of carcinoembryonic antigen (CEA) (> 5.0 mg/dL) before PM resection was a risk factor for early recurrence (HR 3.275, 95% CI 1.092-9.821; p = 0.034)., Conclusion: The RCC and early recurrence after PM resection were poor prognosis factors of OS. Higher value of CEA before PM resection was an independent risk factor for early recurrence after resection of PM. Comparitive study between surgery and nonsurgery is necessary in patients with higher CEA values., (© 2024. The Author(s), under exclusive licence to The Japanese Association for Thoracic Surgery.)
- Published
- 2024
- Full Text
- View/download PDF
50. Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment.
- Author
-
Maekawa S, Takano S, and Enomoto N
- Subjects
- Humans, Neoplasm Recurrence, Local, Risk Factors, Carcinoma, Hepatocellular virology, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms virology, Liver Neoplasms drug therapy, Antiviral Agents therapeutic use, Hepacivirus drug effects, Sustained Virologic Response, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic complications
- Abstract
The advent of direct-acting antiviral (DAA) therapy has revolutionized hepatitis C virus (HCV) treatment, enabling most HCV-infected patients to achieve a sustained viral response (SVR) easily and safely in a short period. On the other hand, it is gradually being recognized that a significant proportion of patients are still at risk of developing de novo and recurrent hepatocellular carcinoma (HCC), even after HCV elimination, and therefore, elucidation of the risk of de novo and recurrent HCC, investigation of its molecular basis, and construction of accurate prediction models are emerging as new important clinical topics. In this review, we present recent advances regarding these issues., (Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.